Investigators assessed whether a daily service of infectious disease consultation was more effective than weekly consultation to reduce antibiotic use without worsening clinical outcomes.
Study authors compared clinical cure in patients with E coli bacteremic UTI who were stepped down to oral beta-lactams compared to oral fluoroquinolones.
Study authors assessed the efficacy and safety of cefiderocol vs best available therapy in adults with serious carbapenem-resistant Gram-negative infections.
Research authors assessed the safety and efficacy of intravesical bacteriophage therapy compared to placebo and current standard of care for the treatment of urinary tract infection in patients undergoing transurethral resection of the prostate.
A team of investigators conducted a systematic review and meta-analysis to assess whether a shorter-than-recommended duration of antibiotic treatment can be effective for the management of acute uncomplicated cystitis.
In cases of complicated urinary tract infections (UTI) treated with multiple-dose fosfomycin, clinical resolution occurred in 2 of 3 treatment episodes.
Fetroja® (cefiderocol) has been made available by Shionogi for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
Enhanced implementation on adoption of evidence-based antibiotic stewardship in nursing homes focused on the recognition and management of UTIs may improve the quality of antibiotic prescription in nursing homes.
With an improved specificity, an updated algorithm for the detection of UTIs in patients with relapsing MS addresses previous issues concerning the unnecessary prescription of antibiotics, whilst improving accuracy and maintaining safety.
A high dose and continuous infusion of cefoxitin has been associated with clinical success in treating febrile urinary tract infections in men caused by extended spectrum beta-lactamase–producing E coli.
The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of approval of cefiderocol for the treatment of complicated UTIs including pyelonephritis.
Ceftazidime-avibactam was highly active against a large collection of gram-negative bacteria isolated from patients with complicated urinary tract infections.